JOHN KIRKWOOD to Interferon Type I
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Interferon Type I.
Connection Strength
1.233
-
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev. 2007 Oct-Dec; 18(5-6):451-8.
Score: 0.276
-
Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
Score: 0.131
-
Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol. 1995 Jul; 2(4):365-71.
Score: 0.119
-
Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
Score: 0.092
-
Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
Score: 0.084
-
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol. 1989 Dec; 7(12):1764-5.
Score: 0.081
-
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):48-56.
Score: 0.065
-
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul; 103(1):32-6.
Score: 0.060
-
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
Score: 0.058
-
Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
Score: 0.055
-
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med. 1984 Apr; 76(4):593-6.
Score: 0.055
-
Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. J Biol Response Mod. 1983; 2(6):528-39.
Score: 0.050
-
Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod. 1983; 2(6):540-7.
Score: 0.050
-
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
Score: 0.031
-
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep. 1984 May; 68(5):723-6.
Score: 0.014
-
Effect of intravenous recombinant alpha-2 interferon on monocyte Fc-dependent phagocytosis in patients with malignant melanoma. J Interferon Res. 1984; 4(2):215-21.
Score: 0.013